NantKwest Executive Chairman Dr. Patrick Soon-Shiong to Present at 39th Annual J.P. Morgan Healthcare Conference on January 1...
January 06 2021 - 9:00AM
Business Wire
NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer
cell-based therapeutics company, today announced that Dr. Patrick
Soon-Shiong M.D., Executive Chairman of the Board of Directors,
will participate in the 39th Annual J.P. Morgan Healthcare
Conference. He will make a formal presentation and answer questions
at 5:20 a.m. Pacific Time (8:20 a.m. Eastern Time) on Wednesday,
January 13, 2021. Dr. Soon-Shiong will discuss NantKwest’s
previously announced agreement to combine in a stock-for-stock
transaction with ImmunityBio, Inc. The combination, which is
expected to close in the first half of 2021, will create a leading
immunotherapy and cell therapy company focused on oncology and
infectious disease. Dr. Soon-Shiong will also provide an update on
the clinical progress of the two companies’ individual and
collaborative therapies.
A live webcast of the presentation and associated presentation
materials will be available on the NantKwest website at
https://ir.nantkwest.com/ and on the ImmunityBio website at
https://immunitybio.com. A replay will be available after the
completion of the presentation.
About NantKwest
NantKwest (NASDAQ: NK) is an innovative, clinical-stage,
immunotherapy company focused on harnessing the power of the innate
immune system to treat cancer and infectious diseases. NantKwest is
the leading producer of clinical dose forms of off-the-shelf
natural killer (NK) cell therapies. The activated NK cell platform
is designed to destroy cancer and virally-infected cells. The
safety of these optimized, activated NK cells—as well as their
activity against a broad range of cancers—has been tested in phase
I clinical trials in Canada and Europe, as well as in multiple
phase I and II clinical trials in the United States. By leveraging
an integrated and extensive genomics and transcriptomics discovery
and development engine, together with a pipeline of multiple,
clinical-stage, immuno-oncology programs, NantKwest’s goal is to
transform medicine by bringing novel NK cell-based therapies to
routine clinical care. NantKwest is a member of the NantWorks
ecosystem of companies. For more information, please visit
www.nantkwest.com.
About ImmunityBio
ImmunityBio, Inc. is a late stage immunotherapy company
developing next-generation therapies that drive immunogenic
mechanisms for defeating cancer and infectious disease. The
company’s immunotherapy platform is designed to activate both the
innate (natural killer cell and macrophage) and adaptive (T cell)
immune systems to create long-term “immunological memory.” This
novel approach is designed to eliminate the need for high-dose
chemotherapy, improve the outcomes of current CAR T-cell therapies,
and extend beyond checkpoint inhibitors. ImmunityBio has
established three fundamental platforms to drive long-term
immunological memory. These include first-in-class antibody
cytokine fusion proteins, synthetic immune modulators, and
second-generation vaccine vector platforms. ImmunityBio’s lead
cytokine infusion protein, a novel interleukin-15 (IL-15)
superagonist complex (Anktiva), has received Breakthrough Therapy
Designation from the U.S. Food and Drug Administration (FDA) for
BCG-unresponsive CIS non-muscle invasive bladder cancer (NMIBC).
Other indications currently at registration-stage trials include
BCG-unresponsive papillary bladder cancer, first- and second-line
lung cancer, triple-negative breast cancer, metastatic pancreatic
cancer, recurrent glioblastoma, and soft tissue sarcoma in
combination with the company’s synthetic immune modulator
(Aldoxorubicin). ImmunityBio is also developing therapies,
including vaccines, for the prevention and treatment of HIV,
influenza, and the coronavirus SARS-CoV-2 with its
second-generation human adenovirus (hAd5) vaccine platform.
No Offer or Solicitation
This communication is not intended to and does not constitute an
offer to sell or the solicitation of an offer to buy, sell or
solicit any securities or any proxy, vote or approval in any
jurisdiction pursuant to or in connection with the proposed
transaction or otherwise, nor shall there be any sale of securities
in any jurisdiction in which such offer, solicitation or sale would
be unlawful prior to registration or qualification under the
securities laws of any such jurisdiction. No offer of securities
shall be deemed to be made except by means of a prospectus meeting
the requirements of Section 10 of the Securities Act.
Additional Information and Where to Find It
In connection with the proposed transaction, NantKwest intends
to file a registration statement on Form S-4 with the SEC, which
will include a prospectus and joint solicitation statement of
NantKwest and ImmunityBio (the “solicitation
statement/prospectus”). NantKwest may also file other documents
regarding the proposed transaction with the SEC. This communication
does not constitute an offer to sell or the solicitation of an
offer to buy any securities or a solicitation of any vote or
approval. This communication is not intended to be, and is not, a
substitute for such filings or for any other document that
NantKwest may file with the SEC in connection with the proposed
transaction. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION,
INVESTORS AND SECURITY HOLDERS ARE URGED TO CAREFULLY READ THE
ENTIRE REGISTRATION STATEMENT AND SOLICITATION STATEMENT /
PROSPECTUS, WHEN THEY BECOME AVAILABLE, AND ANY OTHER RELEVANT
DOCUMENTS FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR
SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY
BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED
TRANSACTION. Investors and security holders will be able to obtain
free copies of the registration statement and solicitation
statement/prospectus and other documents filed with the SEC by
NantKwest through the website maintained by the SEC at www.sec.gov.
In addition, investors and security holders will be able to obtain
free copies of the prospectus and other documents filed with the
SEC on NantKwest’s website at www.ir.nantkwest.com.
Participants in the Solicitation
NantKwest and certain of its respective directors and executive
officers may be deemed to be participants in the solicitation of
proxies from stockholders of NantKwest in connection with the
proposed transaction under the rules of the SEC. Investors may
obtain information regarding the names, affiliations and interests
of directors and executive officers of NantKwest in NantKwest’s
proxy statement for its 2020 annual meeting of stockholders, which
was filed with the SEC on April 24, 2020, as well as its other
filings with the SEC. Other information regarding the participants
in the proxy solicitation and a description of their direct and
indirect interests, by security holdings or otherwise, will be
included in the registration statement, solicitation statement /
prospectus and other relevant materials to be filed with the SEC by
NantKwest regarding the proposed transaction (if and when they
become available). You may obtain free copies of these documents at
the SEC’s website at www.sec.gov. Copies of documents filed with
the SEC will also be available free of charge from NantKwest using
the sources indicated above.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210106005116/en/
Investors Sarah Singleton NantKwest 844-696-5235, Option
5
Media Andrew Siegel / Greg Klassen Joele Frank, Wilkinson
Brimmer Katcher 212-355-4449
Amy Jobe LifeSci Advisors 315-879-8192
NantKwest (NASDAQ:NK)
Historical Stock Chart
From Mar 2024 to Apr 2024
NantKwest (NASDAQ:NK)
Historical Stock Chart
From Apr 2023 to Apr 2024